Amicar Tablet Generic Gets FDA Approval

Vitruvias Therapeutics and Sunny Pharmtech have received approval from the Food and Drug Administration (FDA) to market a generic equivalent to Amicar (Akorn), an inhibitor of fibrinolysis.

Aminocaprioc Acid Tablets are useful in enhancing hemostasis when fibrinolysis contributes to bleeding. The fibrinolysis-inhibitory effects of aminocaproic acid appear to be exerted principally via inhibition of plasminogen activators and to a lesser degree through antiplasmin activity. In life-threatening situations, transfusion of appropriate blood products and other emergency measures may be required.

Aminocaproic Acid Tablets will be available in 500mg and 1000mg strengths.

For more information visit vitruvias.com.